Company Brainstorm Cell Therapeutics Inc OTC Bulletin Board

Equities

US10501E1029

Biotechnology & Medical Research

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sector Other Biotechnology & Medical Research

Inactive Instrument

End-of-day quote OTC Bulletin Board Other stock markets
- ^USD	-

Apr. 17	Brainstorm Cell Therapeutics Inc. Announces Step Down of Stacy Lindborg as Co-CEO, Effective as of May 9, 2024	CI
Apr. 17	Brainstorm Cell Therapeutics Inc. Announces Management Changes	CI

BrainStorm Cell Therapeutics Inc. is a developer of autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The neurodegenerative diseases include Amyotrophic Lateral Sclerosis (ALS), Progressive Multiple Sclerosis (PMS), Alzheimerâs disease (AD), and others. The Company is engaged in the clinical development and commercialization of the NurOwn technology platform used to produce autologous mesenchymal stem cells- neurotrophic factors (MSC-NTF) cells. NurOwn leverages cell culture methods to induce autologous bone marrow derived MSCs to secrete high levels of NTFs, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival and improve neurological function. Autologous MSC-NTF cells is for the treatment of ALS. It has completed a phase III trial in ALS. Its wholly owned subsidiary, BrainStorm Cell Therapeutics Ltd., holds exclusive rights to commercialize NurOwn technology.

Managers	Title	Age	Since
Chaim Lebovits CEO	Chief Executive Officer	53	07-06-30
Alla Patlis DFI	Director of Finance/CFO	37	12-12-22
Netta Blondheim-Shraga CTO	Chief Tech/Sci/R&D Officer	-	22-05-11
Bob Dagher CTO	Chief Tech/Sci/R&D Officer	55	23-07-16
Yael Gothelf CTO	Chief Tech/Sci/R&D Officer	-	06-12-31
Stacy Lindborg BRD	Director/Board Member	53	20-05-31
Uri Yablonka BRD	Director/Board Member	47	14-06-05
Antal Pearl-Lendner LAW	General Counsel	-	22-05-11
Mary Kay Turner LAW	General Counsel	-	17-08-06
Yossef Levy PRN	Corporate Officer/Principal	-	-

Members of the board	Title	Age	Since
Irit Arbel FOU	Founder	64	00-09-21
Uri Yablonka BRD	Director/Board Member	47	14-06-05
Jacob Frenkel CHM	Chairman	81	20-03-29
Menghisteab Bairu BRD	Director/Board Member	63	21-10-27
Anthony J. Polverino BRD	Director/Board Member	61	18-02-04
Stacy Lindborg BRD	Director/Board Member	53	20-05-31
Nir Naor BRD	Director/Board Member	50	23-06-19

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	68,341,857	59,284,308 ( 86.75 %)	0	86.75 %

Name	Equities	%	Valuation
Kevin Ness 6.247 %	3,060,000	6.247 %	2 M $
Chaim Lebovits 5.838 %	2,859,412	5.838 %	2 M $
Abbhi Investments LLC 4.442 %	2,175,853	4.442 %	1 M $
Vanguard Global Advisers LLC 2.906 %	1,423,310	2.906 %	804 170 $
BlackRock Institutional Trust Co. NA 0.9392 %	460,027	0.9392 %	259 915 $
Stacy Lindborg 0.8645 %	423,435	0.8645 %	239 241 $
Geode Capital Management LLC 0.7289 %	357,041	0.7289 %	201 728 $
Liberty Wealth Management LLC 0.6944 %	340,150	0.6944 %	192 185 $
Bob Dagher 0.5165 %	253,000	0.5165 %	142 945 $
Weaver Consulting Group LLC 0.4070 %	199,356	0.4070 %	112 636 $

Brainstorm Cell Therapeutics, Inc.

1325 Avenue of Americas 28th floor

10019, New York

+201 488 0460

http://www.brainstorm-cell.com

address Brainstorm Cell Therapeutics Inc

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+49.22%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research